Vincent Angotti Buys 213,310 Shares of Talphera (NASDAQ:TLPH) Stock

Talphera, Inc. (NASDAQ:TLPH) CEO Vincent Angotti purchased 213,310 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average cost of $0.59 per share, with a total value of $125,852.90. Following the acquisition, the chief executive officer owned 800,705 shares in the company, valued at $472,415.95. This represents a 36.31% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Talphera Stock Performance

TLPH traded up $0.07 during midday trading on Wednesday, hitting $0.80. 427,472 shares of the company traded hands, compared to its average volume of 209,643. Talphera, Inc. has a 52-week low of $0.38 and a 52-week high of $1.57. The business has a 50 day simple moving average of $0.88 and a two-hundred day simple moving average of $1.05.

Talphera (NASDAQ:TLPH) last announced its earnings results on Monday, March 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. Equities analysts anticipate that Talphera, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Talphera currently has an average rating of “Hold” and a consensus target price of $6.00.

Institutional Investors Weigh In On Talphera

Several hedge funds and other institutional investors have recently made changes to their positions in TLPH. Group One Trading LLC boosted its stake in Talphera by 3,224.0% during the third quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after buying an additional 29,500 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Talphera in the 3rd quarter worth $29,000. Persistent Asset Partners Ltd acquired a new stake in shares of Talphera in the 4th quarter worth $42,000. Mariner LLC raised its holdings in shares of Talphera by 132.0% during the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after acquiring an additional 33,000 shares during the period. Finally, Dauntless Investment Group LLC purchased a new position in shares of Talphera during the 3rd quarter worth $89,000. Institutional investors and hedge funds own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.